Alzheon, a privately-held biopharmaceutical company with a focus on Alzheimer's, announced on Monday that researchers had discovered a naturally-occurring substance in the human brain that suppresses the production of a protein linked to the disease.
The substance, which has been named as 3-sulfopropanoic acid (3-SPA), is the primary metabolite of tramiprosate (homotaurine), the active ingredient in Alzheon's ALZ-801. This news comes after extensive research, which Alzheon says has allowed it to come to firm conclusions about the nature of 3-SPA and its role in fighting Alzheimer's disease.
3-SPA inhibits the formation of the neurotoxic beta amyloid (AB) oligomers, the key force behind the escalation of Alzheimer's symptoms. The company reports that 3-SPA levels were up to 12 times greater in Alzheimer's patients taking ALZ-801 than those on placebo.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze